<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Electronic Health Records | Yau Research Group</title>
    <link>https://cwcyau.github.io/tag/electronic-health-records/</link>
      <atom:link href="https://cwcyau.github.io/tag/electronic-health-records/index.xml" rel="self" type="application/rss+xml" />
    <description>Electronic Health Records</description>
    <generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Thu, 07 Aug 2025 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://cwcyau.github.io/media/icon_hu_91b8b2faea5b4fd3.png</url>
      <title>Electronic Health Records</title>
      <link>https://cwcyau.github.io/tag/electronic-health-records/</link>
    </image>
    
    <item>
      <title>SurvivEHR preprint now available</title>
      <link>https://cwcyau.github.io/post/2025-08-07_survivehr_medrxiv/</link>
      <pubDate>Thu, 07 Aug 2025 00:00:00 +0000</pubDate>
      <guid>https://cwcyau.github.io/post/2025-08-07_survivehr_medrxiv/</guid>
      <description>&lt;p&gt;A preprint of work by &lt;a href=&#34;../author/charles-gadd&#34;&gt;Charles Gadd&lt;/a&gt; describing &lt;a href=&#34;https://www.medrxiv.org/content/10.1101/2025.08.04.25332916v1&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&amp;ldquo;SurvivEHR: a competing risks, time-to-event foundation model for multiple long-term conditions from primary care electronic health records&amp;rdquo;&lt;/a&gt; is now available on medRxiv.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Multiple long-term conditions (MLTCs) or multimorbidity &amp;ndash; the co-occurrence of multiple chronic conditions &amp;ndash;presents a growing challenge for primary care. Current predictive models often target single outcomes and overlook the complexities of time-to-event risk in real-world, longitudinal health data. Here, we present SurvivEHR, a generative transformer-based foundation model trained on over 7.6 billion coded events from 23 million patients in UK primary care. SurvivEHR introduces a competing risk time-to-event pretraining objective that enables accurate forecasting of future diagnoses, investigations, medications, and mortality. We demonstrate that SurvivEHR achieves strong risk stratification performance, captures clinically meaningful trajectories, and outperforms benchmark survival models across multiple tasks. The model also transfers effectively to fine-tuned prognostic tasks, particularly in low-resource settings. By learning patient trajectories directly from routine health records, SurvivEHR offers a scalable and privacy-preserving approach for building generalisable clinical risk tools that address the complexity of MLTCs in primary care..&amp;rdquo;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>New report on Synthetic Data for Development of AI</title>
      <link>https://cwcyau.github.io/post/2025-07-01_phg_synthetic/</link>
      <pubDate>Tue, 01 Jul 2025 00:00:00 +0000</pubDate>
      <guid>https://cwcyau.github.io/post/2025-07-01_phg_synthetic/</guid>
      <description>&lt;p&gt;Christopher Yau has contributed as a member of the expert working group to a new report &lt;a href=&#34;2025-08-07_SurvivEHR_medrxiv.md&#34;&gt;&amp;ldquo;The Synthetic Data for Development of AI as a Medical Device&amp;rdquo;&lt;/a&gt; now available via PHG Foundation:&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Synthetic data is artificially generated data that reflects the properties and relationships found in real data. While synthetic data can play an important role in AIaMD development, its use in regulatory submissions introduces specific considerations, especially when it constitutes a substantial part of the evidence package.&lt;/p&gt;
&lt;p&gt;The Synthetic Data for Development of AI as a Medical Device (AIaMDs) report, produced by the Medicines and Healthcare products Regulatory Agency (MHRA) and the PHG Foundation, outlines these considerations, building on and complementing existing regulatory guidance. This marks an important and exciting first step for manufacturers and notified bodies collectively navigating this evolving landscape. The report provides crucial groundwork, though more work is required to move past these preliminary ideas.&amp;rdquo;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Multiple Long-Term Conditions Research Update</title>
      <link>https://cwcyau.github.io/post/2023-10-12_mltc/</link>
      <pubDate>Thu, 12 Oct 2023 00:00:00 +0000</pubDate>
      <guid>https://cwcyau.github.io/post/2023-10-12_mltc/</guid>
      <description>&lt;p&gt;We continue to contribute to the &lt;a href=&#34;https://mumpredict.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;MUM-PREDICT&lt;/a&gt; and &lt;a href=&#34;https://www.birmingham.ac.uk/research/applied-health/research/optimal/index.aspx&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;OPTIMAL&lt;/a&gt; projects over the last six months including:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://openresearch.nihr.ac.uk/documents/3-21&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Artificial Intelligence for Multiple Long-term conditions (AIM): A consensus statement from the NIHR AIM consortia&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://bmjopen.bmj.com/content/13/2/e068718.abstract&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Maternal and child outcomes for pregnant women with pre-existing multiple long-term conditions: protocol for an observational study in the UK&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://link.springer.com/article/10.1186/s12916-022-02722-5&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000-2019&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-023-03013-3&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;The development of a core outcome set for studies of pregnant women with multimorbidity&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://bmjopen.bmj.com/content/13/10/e073162.abstract&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Detection and evaluation of signals associated with exposure to individual and combination of medications in pregnancy: a signal detection study protocol&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;
</description>
    </item>
    
    <item>
      <title>New paper with Breaking Free Online on substance abuse</title>
      <link>https://cwcyau.github.io/post/2023-10-01_jamiaopen/</link>
      <pubDate>Sun, 01 Oct 2023 00:00:00 +0000</pubDate>
      <guid>https://cwcyau.github.io/post/2023-10-01_jamiaopen/</guid>
      <description>&lt;p&gt;Congratulations to &lt;a href=&#34;../../author/franziska-gunther&#34;&gt;Franziska Gunther&lt;/a&gt; on her collaborative work with &lt;a href=&#34;https://www.breakingfreeonline.com/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Breaking Free Online&lt;/a&gt; on &lt;a href=&#34;https://academic.oup.com/jamiaopen/article/6/3/ooad072/7259137&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Identifying factors associated with user retention and outcomes of a digital intervention for substance use disorder: a retrospective analysis of real-world data&lt;/a&gt; which has been published in JAMIA Open.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>MIE 2023 success </title>
      <link>https://cwcyau.github.io/post/2023-05-22_mie2023/</link>
      <pubDate>Mon, 22 May 2023 00:00:00 +0000</pubDate>
      <guid>https://cwcyau.github.io/post/2023-05-22_mie2023/</guid>
      <description>&lt;p&gt;Congratulations to &lt;a href=&#34;../../author/franziska-gunther&#34;&gt;Franziska Gunther&lt;/a&gt; on her collaborative work with Breaking Free Online which was presented at &lt;a href=&#34;https://www.mie2023.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;MIE 2023&lt;/a&gt;: &lt;a href=&#34;https://eprints.whiterose.ac.uk/198537/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;On the difficulty of predicting engagement with digital interventions for substance use disorders&lt;/a&gt;.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>MUM-PREDICT: HDRUK Team of the Year</title>
      <link>https://cwcyau.github.io/post/2022-12-31_mumpredict/</link>
      <pubDate>Sat, 31 Dec 2022 00:00:00 +0000</pubDate>
      <guid>https://cwcyau.github.io/post/2022-12-31_mumpredict/</guid>
      <description>&lt;p&gt;We are proud to have been part of a glittering array of publications arising from our contribution to the &lt;a href=&#34;https://mumpredict.org/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;MUM-PREDICT&lt;/a&gt; projects over the last 12 months. The team also won the &lt;a href=&#34;https://www.hdruk.ac.uk/news/winners-announced-for-hdr-uks-annual-awards/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Health Data Research UK Team of the Year 2022 award&lt;/a&gt;:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://link.springer.com/article/10.1186/s41512-022-00137-7&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Protocol for development and validation of postpartum cardiovascular disease (CVD) risk prediction model incorporating reproductive and pregnancy-related candidate predictors&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;[Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000-2019](&lt;a href=&#34;https://link.springer.com/article/10.1186/s12916-022-02722-5]&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;https://link.springer.com/article/10.1186/s12916-022-02722-5]&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://proceedings.mlr.press/v193/gadd22a.html&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;mmVAE: multimorbidity clustering using Relaxed Bernoulli Î²-Variational Autoencoders&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://bmjopen.bmj.com/content/13/2/e068718.abstract&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Maternal and child outcomes for pregnant women with pre-existing multiple long-term conditions: protocol for an observational study in the UK &lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;
</description>
    </item>
    
    <item>
      <title>BIRM-CAM</title>
      <link>https://cwcyau.github.io/event/birmcam/</link>
      <pubDate>Tue, 01 Oct 2019 00:00:00 +0000</pubDate>
      <guid>https://cwcyau.github.io/event/birmcam/</guid>
      <description>&lt;h1 id=&#34;introduction&#34;&gt;Introduction&lt;/h1&gt;
&lt;p&gt;Christopher Yau is a co-investigator in the &lt;a href=&#34;https://birmcam.github.io/birmcam/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;BIRM-CAM&lt;/a&gt; project that is led by Professors Tom Marshall (University of Birmingham) and Sylvia Richardson (MRC Biostatistics Unit, University of Cambridge).&lt;/p&gt;
&lt;h1 id=&#34;multimorbidity&#34;&gt;Multimorbidity&lt;/h1&gt;
&lt;p&gt;Multimorbidity is when people suffer from more than one long-term illness. It is increasingly common as people live longer. It is important because individual illnesses have knock-on effects on others, it is more complex managing multiple than single illnesses, and multimorbid patients are heavy users of medications and health services.&lt;/p&gt;
&lt;p&gt;To understand multimorbidity we need to know which illnesses tend to occur together and which illness combinations most affect health. To adapt health services we need to know which types of people develop multimorbidity: their age, sex, ethnicity, socio-economic status and whether they tend to live in the same households. To learn how to prevent it we need to identify lifestyle factors (physical activity, diet, smoking, alcohol) linked to multimorbidity and the measurements (laboratory test results, weight, blood pressure) that might be early signs.&lt;/p&gt;
&lt;h1 id=&#34;electronic-health-records&#34;&gt;Electronic Health Records&lt;/h1&gt;
&lt;p&gt;Electronic health records are a good source of information on multimorbidity because they include information on the same patient over many years. They include information on illnesses, medications, hospital admissions; measurements (laboratory tests, weight, blood pressure) and lifestyle (smoking, alcohol). Previous research has studied multimorbidity using a variety of statistical methods. It finds some illnesses, such as diabetes and heart disease tend to occur together. But different statistical methods often find different groups of illnesses. We need a single, consistent approach to this type of analysis to ensure we are researching the same groups of illnesses. Previous research generally has not made best use of all the available information. For example, patients are considered either to have or not have diabetes but research did not make use of laboratory measurements (such as blood glucose) identifying some people as likely to develop diabetes. Previous research grouped illnesses according to how commonly they occur together, without giving any special significance to combinations of illnesses linked to risk of death or hospital admission. Clearly such combinations of illness are of more importance. There are more advanced analysis methods which can address these and other shortcomings.&lt;/p&gt;
&lt;h1 id=&#34;the-research&#34;&gt;The Research&lt;/h1&gt;
&lt;p&gt;The first part of our research will develop methods of data analysis. We will review research on different statistical methods for grouping illnesses together. We will hold a workshop involving leading UK researchers in the field to try to agree on the best approach to this type of analysis. Informed by this we will analyse two large databases of electronic health records, each including several million patients. In each database we will identify the groups of illnesses that co-occur and check our findings in the other database. This is considered good practice in analysis. At the end of this step we will produce software to analyse and find groups of illnesses in electronic health records and make this freely available for other researchers to use.&lt;/p&gt;
&lt;p&gt;The next part of our research will use additional information from two large surveys. Both surveys include details not always available in health records e.g. occupation, diet, lifestyle and measures of frailty. One includes 500,000 people the other has information on the same people over a period of 14 years. We will describe the consequences for patients of different combinations of illnesses: their levels of frailty because it is linked to need for social care; development of further illnesses; medications, use of health services and death. We will work with patient advisors to help guide analysis of patients journeys through health services. We will investigate possible causes of multimorbidity including people&amp;rsquo;s social circumstances, the environment, lifestyle (smoking, alcohol, diet and exercise) and laboratory test results that might help indicate causes. This step will point to the areas of environment and lifestyle which should be investigated further as possible causes.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
